Skip to main content

Table 2 Patient details

From: Deciphering molecular mechanisms underlying chemoresistance in relapsed AML patients: towards precision medicine overcoming drug resistance

  Age Sex Diagnosis Karyotype/Mutations ELN risk score WHO AML category De-Novo/secondary AML WBC at diagnosis Extramedullary involvement
P1 27 Female Jan 2019 T (10;11) (p11;q11), del (9) (q13q22) [3]/ Normal [17] Intermediate M4 - acute monoblastic/ monocytic leukemia De novo 1.24 × 1000/mcl No
P2 18 Female Dec 2017 t(8;21) Favorable M1- AML without maturation De novo 3.05 × 1000/mcl No
GR1 38 Male May 2016 Normal Karyotype, NPM1mut Favorable M2- AML with maturation De novo 166 × 1000/mcl No
GR2 62 Male Sep 2018 Normal Karyotype, NPM1mut Favorable M1- AML without maturation De novo 6.6 × 1000/mcl No
GR3 69 Male Jan 2017 Normal Karyotype Intermediate M2- AML with maturation De novo 11.7 × 1000/mcl No
GR4 63 Female Dec 2010 Normal Karyotype Intermediate M1- AML without maturation De novo 4.4 × 1000/mcl No
GR5 28 Male Oct 2013 t(8;21) Favorable M2- AML with maturation De novo 25.8 × 1000/mcl No